[Network Meta-analysis of efficacy and safety of oral Chinese patent medicines combined with conventional western medicine in treatment of hypertension]
- PMID: 35534266
- DOI: 10.19540/j.cnki.cjcmm.20211223.501
[Network Meta-analysis of efficacy and safety of oral Chinese patent medicines combined with conventional western medicine in treatment of hypertension]
Abstract
This study aims to systematically evaluate the effect of oral Chinese patent medicines on hypertension with network Meta-analysis. Randomized controlled trials on the treatment of hypertension with oral Chinese patent medicine combined with conventional western medicine were retrieved from China National Knowledge Infrastructure(CNKI), Wanfang, VIP, SinoMed, PubMed, EMbase, and Cochrane Library(from establishment of the database to August 2021). Two researchers independently screened the articles, extracted the data, and evaluated article quality. Then R 4.1.0 was employed for data analysis. Finally, 195 eligible articles were screened out, involving 22 546 patients and 18 oral Chinese patent medicines. The results of the network Meta-analysis are as follows. In terms of reducing systolic blood pressure(SBP) and diastolic blood pressure(DBP), Xuesaitong, Qiangli Dingxuan Tablets, Songling Xuemaikang Capsules combined with conventional western medicine are superior. In improving blood lipids, the overall effects of Xinmaitong Capsules, Compound Xueshuantong Capsules, Ginkgo Folium preparations, Yindan Xinnaotong Soft Capsules, and Naoxintong Capsules combined with conventional western medicine are outstanding. In terms of regulating endothelial function, Yindan Xinnaotong Soft Capsules, Xinmaitong Capsules, Zhenju Jiangya Tablets, Compound Danshen Dripping Pills, Xuesaitong with conventional western medicine have certain advantages. As for the safety, the incidence of adverse reactions of conventional western medicine combined with oral Chinese patent medicines is lower than that of conventional western medicine alone. In summary, compared with conventional western medicine alone, the 18 oral Chinese patent medicines combined with conventional western medicine in the treatment of hypertension show advantages in improving blood pressure, blood lipids, and endothelial function. Among them, Xuesaitong, Qiangli Dingxuan Tablets, and Songling Xuemaikang Capsules may be the best oral Chinese patent medicines for lowering blood pressure. The conclusion needs to be further verified by more high-quality studies.
Keywords: hypertension; network Meta-analysis; oral Chinese patent medicine; randomized controlled trial.
Similar articles
-
[Network Meta-analysis of oral Chinese patent medicines in treating type 2 diabetes mellitus complicated with angina pectoris of coronary heart disease].Zhongguo Zhong Yao Za Zhi. 2023 Sep;48(18):5078-5090. doi: 10.19540/j.cnki.cjcmm.20230601.502. Zhongguo Zhong Yao Za Zhi. 2023. PMID: 37802850 Chinese.
-
[Network Meta-analysis of Chinese patent medicine in treatment of unstable angina pectoris].Zhongguo Zhong Yao Za Zhi. 2021 Feb;46(3):703-711. doi: 10.19540/j.cnki.cjcmm.20201103.502. Zhongguo Zhong Yao Za Zhi. 2021. PMID: 33645038 Chinese.
-
[Network Meta-analysis of oral blood-activating and stasis-removing Chinese patent medicines in treatment of hypertensive left ventricular hypertrophy].Zhongguo Zhong Yao Za Zhi. 2022 Mar;47(5):1383-1391. doi: 10.19540/j.cnki.cjcmm.20211214.501. Zhongguo Zhong Yao Za Zhi. 2022. PMID: 35343167 Chinese.
-
Efficacy and safety of oral Chinese patent medicines in the treatment of coronary heart disease combined with hyperlipidemia: a systematic review and network meta-analysis of 78 trials.Chin Med. 2023 Dec 13;18(1):162. doi: 10.1186/s13020-023-00866-x. Chin Med. 2023. PMID: 38093294 Free PMC article. Review.
-
[Chinese patent medicines with function of resolving hard lump for cyclomastopathy: network Meta-analysis].Zhongguo Zhong Yao Za Zhi. 2018 Sep;43(17):3562-3572. doi: 10.19540/j.cnki.cjcmm.20180516.005. Zhongguo Zhong Yao Za Zhi. 2018. PMID: 30347927 Chinese.
Cited by
-
Comparative efficacy and safety of ginkgo-based Chinese patent medicines in patients with hypertension: A systematic review and network meta-analysis of randomized clinical trials.Medicine (Baltimore). 2024 May 3;103(18):e37927. doi: 10.1097/MD.0000000000037927. Medicine (Baltimore). 2024. PMID: 38701296 Free PMC article.
-
Efficacy and safety of Qiangli Dingxuan tablet combined with amlodipine besylate for essential hypertension: a randomized, double-blind, placebo-controlled, parallel-group, multicenter trial.Front Pharmacol. 2023 Jul 10;14:1225529. doi: 10.3389/fphar.2023.1225529. eCollection 2023. Front Pharmacol. 2023. PMID: 37492087 Free PMC article.
-
Therapeutic effects and mechanisms of Xinmaitong formula for type 2 diabetes mellitus via GLP-1R signaling.Front Pharmacol. 2025 Apr 9;16:1575450. doi: 10.3389/fphar.2025.1575450. eCollection 2025. Front Pharmacol. 2025. PMID: 40271065 Free PMC article.
-
Chinese patent medicine combined with calcium channel blockers in the treatment of essential hypertension:a Bayes network meta-analysis and systematic review.Front Pharmacol. 2024 Mar 15;15:1321405. doi: 10.3389/fphar.2024.1321405. eCollection 2024. Front Pharmacol. 2024. PMID: 38560355 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical
Research Materials